Pharmaceuticals company FDC announced Q1FY24 results: Operating revenue of Rs 536 crore in Q1FY24 compared to Rs 495 crore in Q1FY23, up 8.4% YoY EBITDA of Rs 122 crore in Q1FY24 compared to Rs 78 crore in Q1FY23, up 56.4% YoY EBITDA% of 22.7% in Q1FY24 compared to 15.8% in Q1FY23 PBT of Rs 141 crore in Q1FY24 compared to Rs 87 crore in Q1FY23, up 61.7% YoY PAT of Rs 110 crore in Q1FY24 compared to Rs 71 crore in Q1FY23, up 55.4% YoY EPS of Rs 6.62 in Q1FY24 compared to Rs 4.23 in Q1FY23, up 56.6% YoY Commenting on the results, management said, "We are pleased to announce that we have achieved growth across all our business segments in the current quarter. Our domestic business segment reported growth of 6% during the quarter, albeit under some price pressure. Notably, our Export Formulation and API business segments exhibited robust YoY growth of 19%. Furthermore, we are delighted to report that our margins and profits have shown improvement which is attributed due to improved sales realization and an increase in other income. We remain focused on sustaining and building upon these advancements in the upcoming periods." Result PDF
Pharmaceutical firm FDC announced Q3FY23 results: Consolidated Q3FY23 and 9MFY23: India Market: The sale of branded formulations in India for Q3FY23 was Rs 318 crore, with a growth of 10.2% on YoY and -14.1% on QoQ. Overall sales in the Indian market accounted for 78% of total consolidated sales for the quarter. For 9MFY23 sales were at Rs 1,109 crore, growth of 8.1% over the same period last year. As per secondary sales data by IQVIA for the quarter that ended Dec 31, 2022, the company delivered strong YoY growth of 17.5% compared to the Indian Pharmaceutical Market (IPM) growth of 10.0% YoY. Export Formulations Market: Formulation sales in the export market were Rs 72 crore in Q3FY23, up by 84.2% over YoY and up by 24.6% over QoQ, accounting for 17% of total consolidated sales. For 9MFY23 sales were Rs 185 crore, up by 55.3% over the same period last year. The main contributor is the USA market, accounting for 47% of total export formulations sales. Export API Market: API sales in the export market were Rs 20 crore in Q3FY23, up by 37.4% over YoY and accounted for 5% of total consolidated sales. For the 9MFY23, sales were Rs 55 crore, up by 31% over the same period last year. Result PDF